Ipsen to move into USA via Tercica
French drugmaker Ipsen has formed an alliance in the USA with the California-based biotechnology company Tercica, which includes the acquisition of a 25% stake in the American enterprise (Marketletter July 24).
Under the terms of the deal, Tercica is to commercialize Somatuline Autogel (lanreotide solution for injection), a drug developed by Ipsen for the treatment of acromegaly, a condition caused by the over-production of growth hormone and which leads to hypertrophy of the limbs.
The agent is already available in over 50 countries and achieved annual turnover of around 82.0 million euros ($104.4 million) in 2005. Tercica has said it expects revenue from the drug in North America of between $125.0-$150.0 million in the period to 2011.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze